Physicians in the US, Germany, and France show gaps in their knowledge of the treatment of of refractory/relapsed chronic ...

The decision to discontinue BTK inhibitor treatment for CLL is complex, with emerging data suggesting that time-limited ...

Treatment with Brukinsa may lower the rates of switching therapies compared with Calquence and Imbruvica in chronic ...

Video content above is prompted by the following: Let’s conclude by discussing our perspectives on the future of CLL treatment. How do you envision the CLL patient experience evolving in the coming ...

The treatment landscape of chronic lymphocytic leukaemia (CLL) was transformed when the small molecule drug ibrutinib ...

HOUSTON — Bruton's tyrosine kinase inhibitors such as ibrutinib, acalabrutinib, and zanubrutinib have revolutionized the ...

Expert Rev Hematol. 2013;6(4):441-449. In conclusion, although age should generally determine the goal of treatment in CLL, the patient's functional status rather than chronological age can be ...

Though research is ongoing, there’s still no cure for CLL. But advances in treatment have increased life expectancy and improved the quality of life for people with CLL. Chronic lymphocytic ...

Alessandra Ferrajoli, MD, discusses the comorbidities that can impact the management of patients with chronic lymphocytic leukemia and some of the available treatment options in this space.

Lifestyle Expert Jennifer Bonner discusses chronic lymphocytic leukemia, or CLL, and the exciting advancements in its ...